Previous close | 90.50 |
Open | 92.00 |
Bid | 92.00 x N/A |
Ask | 93.50 x N/A |
Day's range | 92.00 - 92.00 |
52-week range | 88.00 - 108.00 |
Volume | |
Avg. volume | 0 |
Market cap | 5.152B |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | 29.39 |
EPS (TTM) | 3.13 |
Earnings date | 24 Apr 2023 - 28 Apr 2023 |
Forward dividend & yield | 1.25 (1.42%) |
Ex-dividend date | 28 Feb 2023 |
1y target est | 104.00 |
Ashland (ASH) benefits from healthy demand in most consumer end markets, the Schulke & Mayr acquisition and its pricing and mix improvement actions to counter inflation.
Key Insights Ashland's estimated fair value is US$147 based on 2 Stage Free Cash Flow to Equity Ashland is estimated to...
Ashland (ASH) benefits from strength in its global pharma business, the Schulke & Mayr acquisition and its pricing and mix improvement actions to counter inflation.